RVPH
Reviva
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
RSI Oversold
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RVPH
Reviva Pharmaceuticals Holdings, Inc.
A clinical-stage pharmaceutical company that develops therapies for central nervous system, cardiovascular, metabolic, and inflammatory diseases
10080 N. Wolfe Road, Suite SW3-200, Cupertino, CA 95014
--
Reviva Pharmaceuticals Holdings, Inc. was incorporated in the British Virgin Islands on March 20, 2018. The Company is a late-stage pharmaceutical company dedicated to discovering, developing and seeking to commercialize next-generation treatments for diseases that have significant unmet medical needs and burdens on society, patients and their families. Their current product lines focus on central nervous system, inflammation and cardiometabolic diseases.
Company Financials
EPS
RVPH has released its 2024 Q4 earnings. EPS was reported at -0.15, versus the expected -0.22, beating expectations. The chart below visualizes how RVPH has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
